58 5.4.2.1 Infections chez l'adulte infecté par, p.60 ,
107 14.1.2 Résultats ,
In vitro activity of isavuconazole and comparators against clinical isolates of the Mucorales order, Antimicrobial Agents and Chemotherapy, 2015. ,
De nouvelles mol??cules pour les infections fongiques???, Antibiotiques, vol.11, issue.3, 2009. ,
DOI : 10.1016/j.antib.2009.01.002
Liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients, Journal of Antimicrobial Chemotherapy, 2002. ,
Antifungal agents : Mode of action in yeast cells, 2006. ,
Vidal Recos . Flammarion, cinquième edition, 2013. ,
Micafungin : A new echinocandin. Reviews of anti-infective agents, 2006. ,
DOI : 10.1086/501020
URL : http://cid.oxfordjournals.org/cgi/content/short/42/8/1171
Vivactis Plus, vingt quatrième edition, 2014. ,
Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections, Infection and Drug Resistance, 2013. ,
Pharmacologie fondamentale et clinique. Piccin, neuvième edition, 2004. ,
Amphotericin B: side effects and toxicity, Revista Iberoamericana de Micolog??a, vol.26, issue.4, 2009. ,
DOI : 10.1016/j.riam.2009.06.003
Caspofungin: the first representative of a new antifungal class, Journal of Antimicrobial Chemotherapy, vol.51, issue.3, 2003. ,
DOI : 10.1093/jac/dkg117
Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (secure) : a phase 3, randomised-controled, non-inferiority trial. The Lancet, 2015. ,
An open-label phase 3 study of isavuconazole (VITAL) : focus on mucormycosis, 2014. ,
Antifungal Azoles: Structural Insights into Undesired Tight Binding to Cholesterol-Metabolizing CYP46A1, Molecular Pharmacology, vol.84, issue.1, 2013. ,
DOI : 10.1124/mol.113.085902
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3684827
Does lipid emulsion reduce amphotericin B neohrotoxicity ? a systematic review and meta-analysis, Clinical Infectious Diseases, 2012. ,
DOI : 10.1093/cid/cis290
URL : http://cid.oxfordjournals.org/cgi/content/short/54/12/1774
Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values, Diagnostic Microbiology and Infectious Disease, vol.82, issue.4 ,
DOI : 10.1016/j.diagmicrobio.2015.04.008
Single-Ascending-Dose Pharmacokinetics and Safety of the Novel Broad-Spectrum Antifungal Triazole BAL4815 after Intravenous Infusions (50, 100, and 200 Milligrams) and Oral Administrations (100, 200, and 400 Milligrams) of Its Prodrug, BAL8557, in Healthy Volunteers, Antimicrobial Agents and Chemotherapy, vol.50, issue.1, 2006. ,
DOI : 10.1128/AAC.50.1.279-285.2006
In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp, Journal of Antimicrobial Chemotherapy, 2005. ,
Application of caspofungin in China compared with amphotericin B and fluconazole, Therapeutics and Clinical Risk Management, 2014. ,
DOI : 10.2147/TCRM.S47146
Micafungin : an evidence-based review of its place in therapy, Core Evidence, 2014. ,
Edition du Vidal, quatre-vingt-dixième edition, 2014. ,